It was Dr Bradstreet who first tested for nagalase in autism after reading Dr Yamamoto's paper on HIV/AIDS. Dr Yamamoto used nagalase as a blood marker to record levels of this enzyme throughout a course of 100ng weekly intramuscular injections. Incredibly all 30 test subjects had their nagalase levels normalised after only a few months of treatment. Dr Yamamoto considered these results a success and declared all 30 recovered and follow up tests showed no rise in nagalase levels.

Dr Bradstreet also used the nagalase blood test in his paper, along with the cgi scale, to measure the success of gcmaf in autism. In 85% of cases gcmaf was able to reduce nagalse levels with some falling into the range considered normal. I am not aware of any follow up tests 2 years after publishing his initial results.